Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Clinical Significance of Wnt/β-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer.

Jung SJ, Oh S, Lee GT, Chung J, Min K, Yoon J, Kim W, Ryu DS, Kim IY, Kang DI.

World J Mens Health. 2013 Apr;31(1):36-46. doi: 10.5534/wjmh.2013.31.1.36. Epub 2013 Apr 23.


Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines.

Cronauer MV, Schulz WA, Ackermann R, Burchardt M.

Int J Oncol. 2005 Apr;26(4):1033-40.


The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.

Schweizer L, Rizzo CA, Spires TE, Platero JS, Wu Q, Lin TA, Gottardis MM, Attar RM.

BMC Cell Biol. 2008 Jan 24;9:4. doi: 10.1186/1471-2121-9-4.


Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells.

Liu X, Choi RY, Jawad SM, Arnold JT.

Prostate. 2011 May 15;71(7):766-77. doi: 10.1002/pros.21293. Epub 2010 Oct 28.


Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.

Rajan P, Sudbery IM, Villasevil ME, Mui E, Fleming J, Davis M, Ahmad I, Edwards J, Sansom OJ, Sims D, Ponting CP, Heger A, McMenemin RM, Pedley ID, Leung HY.

Eur Urol. 2014 Jul;66(1):32-9. doi: 10.1016/j.eururo.2013.08.011. Epub 2013 Aug 14.


Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer.

Kawano Y, Diez S, Uysal-Onganer P, Darrington RS, Waxman J, Kypta RM.

Br J Cancer. 2009 Apr 7;100(7):1165-74. doi: 10.1038/sj.bjc.6604976. Epub 2009 Mar 10.


Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.

Dulinska-Litewka J, McCubrey JA, Laidler P.

Curr Med Chem. 2013;20(1):144-57. Erratum in: Curr Med Chem. 2014;21(32):3717.


Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.

Wang G, Wang J, Sadar MD.

Cancer Res. 2008 Dec 1;68(23):9918-27. doi: 10.1158/0008-5472.CAN-08-1718.


The beta-catenin binding protein ICAT modulates androgen receptor activity.

Zhuo M, Zhu C, Sun J, Weis WI, Sun Z.

Mol Endocrinol. 2011 Oct;25(10):1677-88. doi: 10.1210/me.2011-1023. Epub 2011 Sep 1.


Androgen activates β-catenin signaling in bladder cancer cells.

Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B, Li F, Miyamoto H.

Endocr Relat Cancer. 2013 May 20;20(3):293-304. doi: 10.1530/ERC-12-0328. Print 2013 Jun.


p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer.

Clark EL, Hadjimichael C, Temperley R, Barnard A, Fuller-Pace FV, Robson CN.

PLoS One. 2013;8(1):e54150. doi: 10.1371/journal.pone.0054150. Epub 2013 Jan 17.


A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.

Pakula H, Xiang D, Li Z.

Cancers (Basel). 2017 Jan 27;9(2). pii: E14. doi: 10.3390/cancers9020014. Review.


Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.

Horvath LG, Henshall SM, Lee CS, Kench JG, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL.

Int J Cancer. 2005 Jan 20;113(3):415-22.


In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.

Chesire DR, Ewing CM, Gage WR, Isaacs WB.

Oncogene. 2002 Apr 18;21(17):2679-94.


Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor.

Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM.

Cancer Res. 2004 Nov 1;64(21):7918-26. Erratum in: Cancer Res. 2005 Sep 1;65(17):8057.


A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.

Ben Jemaa A, Sallami S, Céraline J, Oueslati R.

Cell Biol Int. 2013 May;37(5):464-70. doi: 10.1002/cbin.10055. Epub 2013 Feb 18.


Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.

Gong Y, Chippada-Venkata UD, Galsky MD, Huang J, Oh WK.

Prostate. 2015 May;75(6):616-27. doi: 10.1002/pros.22945. Epub 2015 Jan 5.


Linking beta-catenin to androgen-signaling pathway.

Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z.

J Biol Chem. 2002 Mar 29;277(13):11336-44. Epub 2002 Jan 15.

Supplemental Content

Support Center